Read this recently published Journal of Chemistry paper discussing how WuXi STA scientists and their partner AstraZenaca collaborated to improve the process for a synthetically challenging atropisomeric KRASG12C inhibitor resulting in a reduced step count and streamlined protecting group strategy to support efficient clinical API manufacture.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.